Omeros’ (OMER) “Buy” Rating Reiterated at D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $36.00 price objective on the biopharmaceutical company’s stock. D. Boral Capital’s price target would suggest a potential upside of 125.45% from the company’s previous close.

OMER has been the topic of several other research reports. WBB Securities reissued a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.67.

Omeros Stock Up 82.5%

Shares of NASDAQ OMER traded up $7.22 during mid-day trading on Wednesday, reaching $15.97. 16,043,196 shares of the company were exchanged, compared to its average volume of 1,678,645. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The company’s 50 day moving average price is $8.71 and its 200 day moving average price is $5.59. The stock has a market capitalization of $1.13 billion, a PE ratio of -7.87 and a beta of 2.48.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, sell-side analysts predict that Omeros will post -3.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OMER. B. Riley Wealth Advisors Inc. purchased a new position in shares of Omeros in the 2nd quarter valued at about $32,000. Harbour Investments Inc. increased its stake in Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 11,971 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of Omeros in the second quarter worth approximately $40,000. Finally, Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.